Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Nov 10, 2022 11:02am

230 Views

Post# 35088459

RE:RE:RE:RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

With US$1.7 Trillion in firepower and Big Pharma facing a looming patent cliff by 2025, Big Pharma like Pfizer is actively seeking breakthrough science and medicines, likw ONCY's platform technology, to replenish their product pipelines.

Unfortunately there are more of "deniers" and "complainers" who have recently appeared here and who will never see what the future s about.

<< Previous

Bullboard Posts

Next >>

How to navigate the ups and downs of investing in AI